Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)

被引：0
|
作者：
Prajapati, Vimal H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rosmarin, David [8 ]
Shumack, Stephen [9 ,10 ,11 ]
Calimlim, Brian M. [12 ]
Takemoto, Shunya [10 ]
Hu, Xiaofei [12 ]
Ladizinski, Barry [12 ]
Warren, Richard B. [13 ]
机构：
[1] Univ Calgary, Div Dermatol, Calgary, AB, Canada
[2] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada
[3] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada
[4] Univ Calgary, Dept Med, Calgary, AB, Canada
[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[6] Dermatol Res Inst, Calgary, AB, Canada
[7] Prob Med Res, Calgary, AB, Canada
[8] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA
[9] Univ Sydney, Sydney Med Sch Northern, Sydney, NSW, Australia
[10] Skin Hosp, Darlinghurst, NSW, Australia
[11] Royal North Shore Hosp Sydney, Sydney, NSW, Australia
[12] AbbVie Inc, N Chicago, IL USA
[13] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
174
引用
收藏
页码：E81 / E81
页数：1
相关论文
共 50 条
  • [41] Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial
    Panes, Julian
    Vermeire, Severine R.
    D'Haens, Geert
    Danese, Silvio
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Bravata, Ivana R.
    Gaya, Daniel
    Peyrin-Biroulet, Laurent
    Dignass, Axel
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2023, 11 (05) : 410 - 422
  • [42] Dupilumab treatment for up to 100 weeks demonstrates sustained improvement in quality of life in adult patients with moderate-to-severe atopic dermatitis (LIBERTY AD OLE)
    Thaci, D.
    Deleuran, M.
    De Bruin-Weller, M.
    Chen, Z.
    Tomondy, P.
    Ardeleanu, M.
    Boklage, S.
    Shumel, B.
    Surendranathan, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 12 - 13
  • [43] Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies
    Kabashima, K.
    Matsumura, T.
    Komazaki, H.
    Kawashima, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 642 - 651
  • [44] Tralokinumab with topical corticosteroids (TCS) improves health-related quality of life (HRQoL) in adults with moderate-to-severe atopic dermatitis (AD): A Phase 2b, randomized, double-blind, placebo-controlled study
    Silverberg, J. I.
    Kragh, N.
    Guttman-Yassky, E.
    Wollenberg, A.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 41 - 42
  • [45] Efficacy and safety of dupilumab with concomitant topical corticosteroids for up to 1 year in moderate-to-severe atopic dermatitis: a randomized, placebo-controlled phase III trial (CHRONOS)
    Blauvelt, A.
    Gooderham, M.
    Foley, P.
    Griffiths, C. E. M.
    Cather, J. C.
    de Bruin-Weller, M.
    Soo, Y.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Shumel, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 10 - 10
  • [46] Lebrikizumab in combination with topical corticosteroids improves quality of life in patients with moderate-to-severe atopic dermatitis: results from a phase III randomized, double-blinded, placebo-controlled trial (ADhere)
    Forman, Seth
    Gutermuth, Jan
    de Bruin-Weller, Marjolein
    Moore, Angela
    Guenthner, Scott
    Wolf, Eric
    Pierce, Evangeline
    Witte, Michael M.
    Zhong, Jinglin
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E109
  • [47] Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis A phase 2b randomized study
    Silverberg, Jonathan, I
    Guttman-Yassky, Emma
    Gooderham, Melinda
    Worm, Margitta
    Rippon, Stephanie
    O'Quinn, Sean
    van der Merwe, Rene
    Kragh, Nana
    Kurbasic, Azra
    Wollenberg, Andreas
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 126 (05) : 576 - +
  • [48] A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up) An interim 24-week analysis
    Katoh, Norito
    Ohya, Yukihiro
    Murota, Hiroyuki
    Ikeda, Masanori
    Hu, Xiaofei
    Ikeda, Kimitoshi
    Liu, John
    Sasaki, Takuya
    Chu, Alvina D.
    Teixeira, Henrique D.
    Saeki, Hidehisa
    JAAD INTERNATIONAL, 2022, 6 : 27 - 36
  • [49] Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
    Lebwohl, M.
    Papp, K.
    Han, C.
    Schenkel, B.
    Yeilding, N.
    Wang, Y.
    Krueger, G. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (01) : 137 - 146
  • [50] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
12345